Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-7.57%||6.47||0.7%||$452.28m|
|GILD||Gilead Sciences, Inc.||-0.76%||67.63||1.0%||$426.45m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.43%||553.24||2.7%||$408.99m|
|XLRN||Acceleron Pharma, Inc.||0.50%||172.94||5.3%||$345.45m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.07%||181.77||1.9%||$259.59m|
|XENE||Xenon Pharmaceuticals, Inc.||2.12%||33.66||0.4%||$178.19m|
|JSPR||Jasper Therapeutics, Inc.||31.57%||16.42||0.0%||$158.53m|
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.